Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Ophthalmology
•
Uveitis and Ocular Immunology
How do you manage checkpoint inhibitor-associated Vogt-Koyanagi-Harada (VKH) disease in patients who have poorly controlled diabetes?
Related Questions
How do you treat idiopathic acute anterior uveitis that recurs immediately after a course of topical corticosteroids?
In a patient with isolated HLA B27+ anterior uveitis, how long would you continue immunosuppressive therapy?
How do you manage Cancer-Associated Retinopathy (CAR) in a patient who doesn’t have a known cancer diagnosis, given the difficulty in finding the underlying cancer and the risks of using immunosuppressive treatments to preserve vision?
How would you approach the management of posterior uveitis caused by Toxoplasma gondii in immunocompromised patients, considering the potential for atypical presentations and treatment resistance?
How do you decide between initiating systemic immunotherapy versus local treatment for uveitis with associated HLA-B27 and spondyloarthropathy?
When should you consider performing an AC tap in patients with suspected herpetic uveitis?
How do you approach perioperative steroids for a quiescent uveitis patient undergoing cataract surgery?
How do you approach the management of bilateral non-infectious uveitis in the pediatric population?
Is it safe to continue azathioprine in a patient with severe bilateral panuveitis (thought to be related to sarcoidosis) and benign ethnic neutropenia, given worsening neutropenia since starting the medication, or should an alternative immunosuppressive agent be considered?
How do you differentiate between ocular involvement due to active tuberculosis versus latent infection in a patient with uveitis and suspected tuberculosis?
